Back to Market返回行情

MLEC Moolec Science S.A.

USHealthcare
$7.33+0.00%ClosedMarket Cap: $5.3M

As of 2026-07-10 16:00

Why MLEC matters now

Moolec Science S.A. (MLEC) is a US stock in Healthcare. The latest InvestLog snapshot shows $7.33 with +0.00% on the session and $5.3M in market capitalization; recent performance reads 1-month +9.07% and YTD +114.14%.

The latest financial table shown here is FY 2024, with revenue of $333.6M, net income of $-111.5M, and EPS of $-258.75. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -506.8%.

The latest indexable market news headline is "Moolec Science Successfully Completes 2026 GLASO Commercial Planting Campaign in the United States" from Accesswire.

Additional event context on this page matters because analyst consensus is Buy with a median target of $45.00; recent insider activity includes Core Daniel Joaquin filing . These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

-0.05

P/S

0.02

EV/EBITDA

-3.65

DCF Value

$3,180.96

FCF Yield

-506.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

34.2%

Operating Margin

-3.1%

Net Margin

-33.4%

ROE

376.8%

ROA

-54.4%

ROIC

-5.3%

Financials

PeriodRevenueNet IncomeEPS
FY 2024$333.6M$-111.5M$-258.75
Q2 2024$2.6M$-2.4M$-0.90
Q1 2024$1.6M$-1.9M$-0.75
Q4 2023$1.5M$-2.5M$-1.05

Analyst Ratings

Consensus

Buy

Target (Consensus)

$45.00

Target (Median)

$45.00

Target Range

$45.00 - $45.00

Strong Buy: 1Buy: 0Hold: 0Sell: 0Strong Sell: 0

Trading Activity

Insider Trades

Core Daniel Joaquindirector
Sell2026-04-15
Falottico Valeria Inesofficer: Chief Financial Officer
Sell2026-03-19
Falottico Valeria Inesofficer: Chief Financial Officer
Sell2026-03-19
Falottico Valeria Inesofficer: Chief Financial Officer
Sell2026-03-19
Falottico Valeria Inesofficer: Chief Financial Officer
Sell2026-03-19

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

LU

Exchange

Beta

0.27

Moolec Science S.A. is an innovative biotechnology firm specializing in the development of plant-grown animal proteins. Leveraging a transformative method called Molecular Farming, the company is poised to disrupt the alternative protein market. Their product lines and research and development efforts capitalize on the inherent agricultural benefits of select host crops, such as soybeans and peas. Globally, Moolec maintains operations across the United States, Europe, and South America. Established in 2008, the company is headquartered in Luxembourg.